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Abstract
AIM: To investigate the precise role of membrane type
1-matrix metalloproteinase (MT1-MMP) in hepatocellular
carcinoma (HCC) metastasis.
METHODS: Human HCC cells Hep3B with overexpression
of MT1-MMP were established by stable transfection, and
compared with control cells carrying the empty vector.
Cells were examined in vivo for their differences in the
metastatic ability of athymic nude mice, and analyzed
in vitro for their differences in invasion ability by invasion
chamber coated with Matrigel, adhesion towards collagen
I and migration through culture chamber. Cell proliferation
and apoptosis in adherent and suspension status were
evaluated by MTT and flow cytometry analysis.
RESULTS: We found that overexpression of MT1-MMP
could increase intrahepatic metastasis in nude mice with
orthotopic implantation of HCC cells (incidence of 100%
[MT1-MMP transfectants] vs 40% [vector control
transfectants], P<0.05). MT1-MMP could also enhance
cell invasion through Matrigel (107.7 vs 39.3 cells/field,
P<0.001), adhesion towards matrix (0.30 vs 0.12
absorbance unit at 540 nm, P<0.001), cell migration
(89.3 vs 39.0 cells/field, P<0.001), and cell proliferation
(24.3 vs 40.5 h/doubling, P<0.001). We also observed
that MT1-MMP supported cell survival (71.4% vs 23.9%,
P<0.001) with reduced apoptosis (43.7% vs 51.0%, P<0.05)
in an attachment-free environment.
CONCLUSION: MT1-MMP overexpression could enhance
metastasis. In addition to its active role in matrix degradation
during tumor invasion, MT1-MMP enhances tumor cell
survival upon challenge of detachment, which is important
during metastasis when cells enter the circulation.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Membrane type 1-matrix metalloproteinase (MT1-MMP
or MMP14) is the well-characterized transmembrane MMP.
It triggers the activation cascade of  other pro-MMPs via
the activation of pro-MMP2[1] and pro-MMP13[2] resulting
in the cleavage of a complex array of extracellular matrix
proteins. MT1-MMP itself also aids in maintaining the
homeostasis of extracellular matrix by regulating the turnover
of types I-III collagens, fibronectin, vitronectin, laminin,
fibrin, and proteoglycan[3,4] for tissue remodeling and
development. MT1-MMP knock-out mice show inadequate
collagen turnover resulting in dwarfism, osteopenia, arthritis,
connective tissue abnormalities, and early postnatal death[5].
In addition, MT1-MMP deficiency causes impaired
endochondral ossification and angiogenesis[6].
MT1-MMP is involved in the progression of different
malignancies[7], and localizes in invadopodia of invading
tumor cells tethering extracellular matrix breakdown at
invasive front[8,9]. Numerous studies support its role in cancer
dissemination by demonstrating that MT1-MMP alters
cell behaviors through proteolysis[10-13]. All these point out
that MT1-MMP is a versatile enzyme that contributes to
invasion and metastasis through numerous mechanisms[14].
Our recent study has revealed upregulation of MT1-MMP
specifically in hepatocellular carcinoma (HCC) tissues with
venous invasion (P<0.001)[15]. HCC is a hypervascular tumor,
in which venous invasion is common and an important risk
factor for tumor metastasis. Earlier studies of MT1-MMP
focused on its increased expression in invasive HCC[16-20],
association with extracellular matrix remodeling[21], poor
prognosis[19], and induction of its expression by HBV X
protein[22]. In this study, we demonstrated a novel role of
MT1-MMP in metastasis, where cell survival in an
attachment-deprived condition was maintained with reduced
apoptosis. The current data indicate that MT1-MMP plays
an important role in supporting cell survival when cells enter
the circulation during metastasis, in addition to its prominent
role in matrix degradation during tumor invasion.
MATERIALS AND METHODS
Construction of plasmid
Full-length human MT1-MMP cDNA was PCR-amplified
using the first-stranded cDNA reverse-transcribed from total
RNA of  normal liver according to the published sequence
(GenBank accession number NM 004995) using specific
primers (forward primer: 5’-GAGAT ATCAT GTCTC
CCGCC CCAAG A-3’; reverse primer: 5’-CCTCT AGACA
CCTGC TGCCA CTG-3’) under the conditions: at 94 ℃
for 10 min; at 94 ℃ for 1 min, at 60 ℃ for 1 min, at 68 ℃
for 1 min for 30 cycles by Platinum® Taq DNA polymerase
high fidelity (Invitrogen, Carlsbad, CA, USA). Expression
construct was made by cloning the PCR product into a
mammalian expression vector, pcDNA3.0 (Invitrogen).
Cell culture and transfections
Human HCC cell line Hep3B purchased from the American
Type Culture Collection (ATCC, Rockville, MD, USA) was
cultured in DMEM supplemented with 100 mL/L fetal
bovine serum (FBS), 2 mmol/L L-glutamine, 100 U/mL
penicillin, and 100 g/mL streptomycin. Constructs were
transfected using the LipofectAMINE reagent (Invitrogen)
according to the protocol suggested by the manufacturer.
Stable transfectants were selected in DMEM complete
medium with 400 g/mL Geneticin (USB, Cleveland, OH,
USA) for 3 wk. Hep3B cells stably transfected with empty
pcDNA3.0 vector were used as control for all the experiments,
in comparison with the MT1-MMP transfectants. Expression
levels of MT1-MMP in transfectants were compared by
semi-quantitative RT-PCR and Western blotting.
Intrahepatic tumor model
Male BALB/c nu/nu (nude) mice were obtained from the
Charles River Laboratories (Wilmington, MA, USA) and
the study protocol was approved by the Committee on the
Use of  Live Animals in Teaching and Research of  the
University of Hong Kong. Hepatic tumor was generated
by slow intrahepatic injection of 2×106 cells into the left
liver lobe of  a 7-wk-old mouse during laparotomy. Ten
mice were injected for each transfectant and were killed
60 d after the operation. After macroscopic examination
and measurement, livers, hearts, spleens, lungs, kidneys, and
pancreas were harvested. Intrahepatic metastasis was defined
macroscopically as nodules that were clearly distinguishable
from primary tumors by naked eyes or microscopically as
clusters of tumor cells with -fetoprotein (AFP) expression
confirmed by immunohistochemistry and hematoxylin and
eosin staining on paralleled sections.
MT1-MMP RNA expression quantitation
MT1-MMP RNA expression level was assessed by semi-
quantitative RT-PCR using MT1-MMP specific primers
(forward primer as described above; reverse primer: 5’-
AATGC TCGAG CCCCA GGGCA-3’) and control 18S
rRNA (forward primer: 5’-CTCTT AGCTG AGTGT
CCCGC-3’ and reverse primer: 5’-CTGAT CGTCT
TCGAA CCTCC-3’). PCR for MT1-MMP and 18S rRNA
was first performed for 20-32 and 10-32 cycles, respectively.
The PCR product was electrophoresed in agarose gel and
the intensity was quantified by densitometric scanning using
a gel-imaging system and UVP GelWorks ID Intermediate
version 3.01 (Ultra Violet Products Ltd, Cambridge, UK).
The number of cycles at linear increase of PCR product
was chosen for comparison. The relative MT1-MMP RNA
level was determined as the MT1-MMP intensity normalized
by the 18S rRNA intensity of respective samples.
Immunohistochemistry
For immunohistochemical staining, AFP polyclonal
antibody (DAKO, Carpinteria, CA, USA) and Ki67 mAb
(BD PharMingen, San Diego, CA, USA) were used at
1:3 000 and 1:100, respectively. Paraffin-embedded tissues
were cut into 4-m-thick sections, dewaxed, rehydrated in
graded ethanol and antigen retrieved by boiling for 10 min
in a citrate buffer, pH 6.0. Endogenous peroxidase activity
was quenched by DAKO peroxidase block, followed by
30-min incubation with primary antibody. After being washed
with PBS, localization of protein was detected using the
DAKO EnvisionTM+System. The tissue sections were
counterstained with hematoxylin.
Protein extraction and Western blotting
Total protein was extracted with urea buffer (9 mol/L urea,
50 mmol/L Tris-Cl, pH 7.5) in the presence of  CompleteTM
protease inhibitor cocktail (Roche, Mannheim, Germany).
Twenty micrograms of  total protein was analyzed with
2 g/mL MT1-MMP polyclonal antibody (AGI, Sunnyvale,
CA, USA).
Immunoreactive bands were visualized with the Enhanced
Chemiluminescence Western Blotting Detection Kit (Amersham
Biosciences, Buckinghamshire, UK). -actin antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) served as loading
control. The reactive bands in the exposed films were quantified
by densitometric scanning as described above. The relative
amount of  MT1-MMP level for the active form (62 ku) and
the total MT1-MMP (summation of  pro-form, 64 ku; active
form, 62 ku; and cleaved forms, 20-43 ku) were calculated,
respectively, after normalization by the actin reactive band.
Cell proliferation
Three thousand cells per well were seeded at the start of
the experiment. Cell proliferation was assessed using
conversion of  3- [4 ,5-dimethyl thiazol-2- yl ] -2 ,5-
diphenyltetrazolium bromide (MTT, Sigma-Aldrich, St.
Louis, MO, USA) to formazan product at 24-h intervals.
Briefly, 0.5 mg/mL MTT was added to the well for 4 h
and terminated by adding 100 L of 0.1 mol/L HCl/
isopropanol. Absorbance was measured at 540 nm. Cell
proliferation was also assessed by counting the total cell
number. Briefly, 30 000 cells/well were seeded at the
start of the experiment. The cells were trypsinized and
counted at 24-h intervals for 5 d by the trypan blue
exclusion method. The doubling time of the cells was
assessed at the linear phase of the growth curve.
In vitro invasion assay
Fifty thousand cells were seeded in 500 L DMEM in
the upper compartment of the BD BioCoatTM MatrigelTM
Invasion Chamber (Becton Dickinson, Bedford, MA, USA).
The lower compartment was filled with 500 L of
DMEM/10% FBS. After 24 h, cells on the undersurface
of the filters were fixed, stained with hematoxylin and eosin,
and counted under a microscope at a magnification of ×200
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for 10 random fields.
Cell attachment assay
Fifty thousand cells were seeded in 100 L DMEM/
10% FBS in collagen I-coated plates for 1 h. After
extensive washes, adherent cells were fixed and stained
with crystal violet in 10% ethanol. Following washing
with PBS, the incorporated dye was extracted with a
1:1 mixture of 100 mmol/L sodium phosphate, pH 4.
5 and 50% ethanol. Absorbance was read at 540 nm.
Cell migration assay
Fifty thousand cells were re-suspended in 0.5 mL DMEM
and loaded into cell culture insert. The lower chamber
was filled with 0.5 mL DMEM/10% FBS. After 24 h,
cells at the membrane’s undersurface were fixed, stained,
and counted at a magnification of ×200 for four
microscopic fields.
Anoikis assay
Three million cells were held in suspension in poly-
HEMA (Sigma-Aldrich)-coated petri dishes. At indicated
time points, the cells were collected, centrifuged, and
washed once in PBS. Cell clumps were dispersed by a 5-
min treatment of 500 L 0.5 mmol/L EDTA, followed
by an addition of 9.5 mL DMEM/10% FBS. Then, 100
L cells was seeded and the ability to convert MTT to
formazan product was examined as described above for
3 h. The percentage of absorbance value divided by the
absorbance value at 0 h after background correction was
presented. Cells at indicated time points were also
stained with propidium iodide for 15 min followed by
an analysis using the flow cytometer (Becton Dickinson).
Statistical analysis
Each data point represented results from at least three
independent experiments performed in duplicate and was
presented as mean±SD. Comparison between groups
was made with the Student’s t-test and considered
statistically significant if the P value was less than 0.05.
Statistical analysis was carried out using the statistical
software (SPSS version 9.0 for Windows; SPSS, Chicago,
IL, USA).
RESULTS
Establishment of stable MT1-MMP overexpression transfectant
To examine the biological function of MT1-MMP, we
first established a stable Hep3B transfectant that
overexpressed MT1-MMP. Semi-quantitative RT-PCR
(Figure 1A) confirmed that the MT1-MMP RNA
transcript level in overexpressing transfectants increased
by 2.9-fold compared to vector control transfectants,
whereas the Western blot analysis (Figure 1B) showed
that in MT1-MMP transfectants there was an 1.5-fold
increase of active MT1-MMP and 2.0-fold increase of
total reactive forms of MT1-MMP protein compared to
the vector control. The higher levels of the 43 and 20
ku MT1-MMP, which are cleavage products generated
by active MMP2, indirectly evidenced the increased active
MMP2 generated by MT1-MMP in overexpression
transfectants compared to the vector control[23,24].
MT1-MMP increased metastasis and tumorigenicity
The stable transfectants were inoculated into the left liver
lobe of the athymic nude mice to study the effect on
metastasis (Figure 2). The intrahepatic tumors grew within
the liver and the tumor nodules were physically close to
each other. Physical separation of tumor and non-tumor
liver tissues by detailed dissection for weight and volume
measurement became infeasible, because this would ruin
the subsequent histological analysis for tumor margin
assessment of these nodules. Hence, the size was presented
as the greatest dimension measured reflecting the weight
and volume of the tumor mass. In 60 d, MT1-MMP
overexpression resulted in a higher incidence of xenograft
formation and a larger primary tumor (incidence of  80%
and size of 2.0±1.3 cm), as compared to the control
group (incidence of 50% and size of 0.8±0.5 cm; Table 1),
supporting its role in enhancing tumorigenicity and
Figure 1  Establishment of stable MT1-MMP transfectants. A: RNA transcript
levels were compared in linear phases by semi-quantitat ive RT-PCR after
Table 1  Summary of in vivo tumorigenicity assay
                Primary tumor                               Metastasis
Incidence     Size (cm)          tumor
MT1-MMP      8/10       2.0±1.3             8/8
Vector control      5/10       0.8±0.5             2/5
MT1-MMP overexpression resulted in significantly larger primary tumor
and frequent metastasis.
normalization with 18S level; B: protein expression levels were compared by
Western blotting analysis after normalization with actin level.
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growth. The possibility of tumor implantation into the portal
vein during the experiment was excluded, because portal
vein injection resulted in multiple liver tumors (data not
shown).
In the non-injection liver lobes, a higher incidence
of variably sized tumor nodules was found in the MT1-
MMP transfected group (Figure 2). Microscopic metastasis
was further confirmed by AFP staining, as Hep3B cells
expressed AFP but not the normal mouse hepatocytes.
The microscopic metastases were counted by the presence
of clusters of AFP-positive cells, as the clinical significance
of single solitary AFP-positive tumor cells was unknown.
In general, more intrahepatic metastases were found in the
MT1-MMP transfected group than in the vector control
group (100% and 40%, respectively; Table 1). No AFP-
producing cell was found in kidneys, lungs, spleens, hearts,
and pancreas.
MT1-MMP enhanced tumor dissemination and growth
Enhanced metastasis in vivo further prompted us to look
Figure 2  Tumorigenicity and metastasis in vivo enhanced by MT1-MMP. A1-4: Large primary tumor nodule with prominent metastases produced by MT1-MMP
overexpression; B1-4: Small primary tumor nodule and rare metastasis produced by vector control transfectants; C1-2: Tumor-free control liver injected with saline.
Primary tumors, metastases, and injection site were indicated by dotted lines, arrows, and an asterisk, respectively. Sections from all tissues collected were then
subjected to AFP staining.
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into the sequential steps of metastasis by in vitro assays. In a
standard Boyden chamber assay, MT1-MMP transfectants
significantly increased the number of cells that invaded
through Matrigel-coated filters by 174.0% (107.7±15.5 and
39.3±12.1 cells/field, respectively; P<0.001; Figure 3A).
Furthermore, 150% more MT1-MMP transfectants adhered
onto collagen I compared to the control within a fixed time
(0.3±0.02 and 0.12±0.03 absorbance unit at 540 nm,
respectively; P<0.001; Figure 3B). When the transfectants
were plated into plain transwells without a Matrigel layer,
increased MT1-MMP enhanced cell migration by 129.0%
(89.3±6.7 and 39.0±2.3 cells/field, respectively; P<0.001;
Figure 3C). Collectively, increased MT1-MMP facilitated
cells in suspension to arrest onto collagen I (cell attachment
to matrix during metastasis at the secondary site), enhanced
their directional cell motility and thereby promoted invasion
through matrix. This was particularly important during
extravasation.
Increase in tumor size in vivo led us to examine the cell
proliferation rate. Intense Ki67 staining was observed in
MT1-MMP xenografts (Figure 4A) indicating MT1-MMP
enhanced growth in vivo. Cell proliferation of transfectants
in culture was monitored by the assessment of mito-
chondrial activity in MTT assay (Figure 4B) and counting
the total cell number (Figure 4C) at 24-h intervals over 5 d,
and both assay methods demonstrated that MT1-MMP
promoted cell proliferation in vitro. The doubling time of
MT1-MMP overexpressing transfectants and control
transfectants was 24.3 and 40.5 h, respectively. Taken
together, MT1-MMP increased cell proliferation in vivo
and in vitro.
MT1-MMP reduced anoikis
Adherent cells undergo apoptosis shortly after loss of
cell-substratum adhesion, a phenomenon known as
Figure 3  Cell invasion, adhesion efficiency, and cell motility in vitro enhanced by MT1-MMP. A: Cell invasive ability in standard Boyden chamber; B: Adhesion
efficiency on collagen I; C: Directional migration ability by cell motility assay.
Figure 4  Cell proliferation in vivo and in vitro enhanced by MT1-MMP. A1-2: Primary tumors in athymic nude mice examined by Ki67 staining; B: Cells examined
by MTT assay; C: Cell number counted at regular time intervals.
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“anoikis”. Cell viability under attachment-deprived
conditions is critical after the cells enter the circulation
during the process of metastasis. To examine the cell
viability under attachment-deprived conditions, the
transfectants were prepared as single cell suspension,
challenged by anoikis by plating out in attachment-
deprived dishes and examined by MTT assay (Figure 5).
As reflected by the conversion of MTT to its substrate,
MT1-MMP t rans fec tant s  maint a ined  a  h igher
metabolism than the vector control during the 24 h
de t a ch me nt .  B y  24  h  in  a n  a t t a c hm en t - f r ee
environment, MT1-MMP transfectants maintained 71.
4% metabolic activity, whereas the metabolic activity of
control transfectants declined to only 23.9%.
To evaluate if  the MT1-MMP level plays a role in
anoikis, the two transfectants at 0 and 24 h after detachment
were subjected to propidium iodide staining and then analyzed
by the flow cytometer. Difference in detachment-induced
death was observed between the MT1-MMP and vector
control transfectants at 24 h (43.7±2.0% vs 51.0±4.1%,
respectively; P<0.05). In summary, MT1-MMP enhanced
cell survival with reduced apoptosis upon detachment
challenge.
Figure 5  MT1-MMP delayed anoikis. The cell metabolic activity of two
transfectants after detachment was compared.
DISCUSSION
MT1-MMP is crucial in HCC progression[15,17,20-22]. Here,
we have demonstrated that MT1-MMP protected tumor
cells from anoikis, in addition to its classical roles in tumor
invasion to pave way for tumor cells to migrate in circulation
for distal metastasis after crossing the extracellular matrix
and basement membrane. Such a finding is important
because even when large number of tumor cells enter the
circulation successfully, only a small percentage of tumor
cells can actually metastasize due to “metastastic
inefficiency”[25-28], the failure to establish metastasis. Only
if  tumor cells have sustained survival in circulation, the
attachment-deprived environment, there would be successful
metastasis. Thus, the protection from anoikis contributed
by MT1-MMP in the first 24 h upon detachment is of
paramount importance during HCC invasion and metastasis.
Increased intrahepatic metastasis by MT1-MMP was
observed in the spontaneous metastasis assay performed
in vivo. In vitro, MT1-MMP was also shown to enhance
invasion through matrix, adhesion to collagen I and in
directional cell migration. Collagen I is the most
abundant extracellular matrix component in liver,
especially in cirrhotic liver. Enhanced cell attachment
to  col lagen I  was  observed  in the  MT1-MMP
transfectants in suspension status. Thus, MT1-MMP
could also facilitate cell attachment at a new site for
metastasis , aside from its  leading role in matr ix
degradation and enhanced cell migration ability for cell
invasion to take place to leave the primary site.
Apoptosis is the “rate-determining” step subsequent to
the cells entering the circulation. Others have reported that
inhibition of apoptosis in the first 24 h could already enhance
lung metastasis[25,29,30]. In the current study, MT1-MMP
expression conferred a survival advantage in the attachment-
deprived environment. Notably, MT1-MMP expression also
contributed to evasion of apoptosis in suspension status,
although the percentage difference was not enormous but
statistically significant. The significant gain in survival
advantage but marginal improvement in evasion of apoptosis
by MT1-MMP overexpression during suspension status
could be due to a number of reasons. The remaining viable
control cells became dormant (or less active in converting
MTT to a formazan product) in adverse conditions, whereas
the viable MT1-MMP transfectant was able to withstand
the stress and maintained the cell metabolism. Therefore,
even when a similar proportion of cells died, a considerable
difference in cell metabolism between two transfectants
was observed. The higher cell metabolism of  MT1-MMP
transfectants in suspension culture also suggests that
MT1-MMP may still underpin proliferation and, therefore,
promotes the selection for a population of cells that are
more tumorigenic and resistant to anoikis. Although other
factors like immune attack and mechanical shear force from
circulation were not taken into account in our experimental
settings, cell survival upon detachment could definitely enhance
metastatic potential. Further, experiments on proliferation
and apoptosis are needed to confirm if  proliferation occurs
during suspension.
Potential mechanisms exist for the contribution of
MT1-MMP to survival advantage during cell suspension
status. Indirect links might be mediated through its enzymatic
activity. MT1-MMP may alter processing of proteins and
thus overrides the apoptotic stimuli during the challenge of
detachment. For instance, MT1-MMP modulation of
integrin processing and downstream regulation of  FAK
signaling pathways[31] are related to apoptotic pathways.
During osteoblast transdifferentiation, MT1-MMP activates
latent transforming growth factor- and maintains osteoblast
survival[32,33]. In support of  this view, MMP1 degradation
of type I collagen has been shown to expose new cryptic
domains that bind to the 3 integrin and trigger survival
signals in melanoma cells[34]. On the other hand, MT1-MMP
might directly link to various pathways[12,31,35,36] leading to
distinct biological outcome in a number of recent studies[36-38].
The localization of MT1-MMP in clathrin-coated pits[39,40]
and caveolae[41-44], which are rich in signaling molecules[45],
also raises the possibility of direct activation of signal
transduction pathways by MT1-MMP. Therefore, it is
conceivable that MT1-MMP can contribute to the activation
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of intracellular pathways.
From therapeutic perspectives, total elimination of
MMP protease function by inhibitors is impossible and
would cause a number of side effects. Nevertheless, the
MMP-related subject is promising in the field of tumor
detection, prognosis, prevention, and therapeutic purposes
in defined situations[46,47]. Our findings have a direct impact
on cancer therapy because molecular understanding of the
biological activities mediated by proteases provides
exciting opportunities for specific interventions in
pathways critical for tumor progression.
In  conc lu s ion ,  MT1-M MP pro motes  HCC
tumorigenicity and intrahepatic metastasis with increased
tumor growth and invasion ability. More importantly,
increased MT1-MMP expression reveals surv ival
advantage and protects HCC cells from apoptosis in the
first 24 h in the attachment-free condition. These results
strengthen the emerging opinion that the role of MT1-
MMP does not only confine to matrix degradation, but
also extends to alteration of cell behaviors including
surv ival  advantage in the  at tachment -depr ived
environment.
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